Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Europe Finance Weekly.
Press releases published on March 20, 2025
SL Green Realty Corp. Announces Common Stock and Preferred Stock Dividends
GlobeNewswire
·
March 20, 2025
NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- SL Green Realty Corp. (NYSE:SLG), Manhattan’s largest office landlord, today announced that its board of directors has declared a monthly ordinary dividend of $0.2575 per share of common stock, which is the …
Vor Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update
GlobeNewswire
·
March 20, 2025
VCAR33 clinical data update planned for first half of 2025 and trem-cel + Mylotarg clinical data update planned for second half of 2025 Anticipate initiation of the first trem-cel+VCAR33 Treatment System clinical trial in second half of 2025 $55.6 million …
LPL Financial Reports Monthly Activity for February 2025
GlobeNewswire
·
March 20, 2025
SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- LPL Financial LLC (“LPL Financial”), a wholly owned subsidiary of LPL Financial Holdings Inc. (Nasdaq: LPLA) (the “Company”), today released its monthly activity report for February 2025. Total advisory and …
Assembly Biosciences Reports Year End 2024 Financial Results and Recent Highlights
GlobeNewswire
·
March 20, 2025
– Four development candidates in clinical studies with data anticipated this year, continuing rapid progress of antiviral pipeline – – Interim Phase 1b proof-of-concept data, including initial efficacy measures, anticipated in fall 2025 for ABI-5366 and …
TELA Bio Reports Fourth Quarter and Full Year 2024 Financial Results
GlobeNewswire
·
March 20, 2025
MALVERN, Pa., March 20, 2025 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the fourth quarter and …
Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
GlobeNewswire
·
March 20, 2025
- Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer - - Announced a clinical trial supply agreement with Regeneron …
Cibus Reports Fourth Quarter Financial Results and Provides Business Update
GlobeNewswire
·
March 20, 2025
A major milestone on March 14th 2025 advanced the EU Trilogue discussions aimed to complete the final text of the New Genomic Techniques (NGTs) or gene editing legislation for the EU; California Rice Commission approved Cibus' field research proposal …
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
GlobeNewswire
·
March 20, 2025
Dose expansion in Phase 1 CARDINAL trial of TERN-701 for chronic myeloid leukemia (CML) expected to initiate in 2Q25 with additional safety and efficacy data in 4Q25 First patient enrolled in Phase 2 FALCON trial of TERN-601 for obesity with 12-week data …
Xcel Energy to Deploy Advanced Virtual Power Plant in Colorado with Itron and Tesla
GlobeNewswire
·
March 20, 2025
LIBERTY LAKE, Wash., March 20, 2025 (GLOBE NEWSWIRE) -- Itron, Inc. (NASDAQ: ITRI), which is innovating new ways for energy providers and cities to manage energy and water, is collaborating with Tesla Inc. to deploy an advanced virtual power plant (VPP) in …
SELLAS Life Sciences Reports Full Year 2024 Financial Results and Provides Corporate Update
GlobeNewswire
·
March 20, 2025
– Announced Positive Outcome of Interim Analysis for its Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) with Next and Final Analysis Planned Upon Reaching 80 Events, Anticipated in 2025 – – Reported Positive Overall …
MacroGenics Provides Update on Corporate Progress and 2024 Financial Results
GlobeNewswire
·
March 20, 2025
Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPC Initiating new LINNET Phase 2 study of lorigerlimab in ovarian cancer Advancing multiple novel topoisomerase 1 inhibitor- …
Credit Acceptance Named 2025 Top Workplaces USA Award Winner
GlobeNewswire
·
March 20, 2025
Southfield, Michigan, March 20, 2025 (GLOBE NEWSWIRE) -- Credit Acceptance Corporation (Nasdaq: CACC) (referred to as the “Company”, “Credit Acceptance”, “we”, “our”, or “us”) has been named a 2025 Top Workplaces USA award winner for the fifth consecutive …
NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update
GlobeNewswire
·
March 20, 2025
Remains on Track to Initiate an Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma in 2025 Data from the Expansion Study to Support Interaction with FDA and Define Regulatory Strategy for NUC- …
Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights
GlobeNewswire
·
March 20, 2025
– Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical trial of SENTI-202 maintaining remission – – Strengthened balance sheet with gross proceeds of …
Erasca Reports Fourth Quarter and Full Year 2024 Business Updates and Financial Results
GlobeNewswire
·
March 20, 2025
Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025 Ongoing Phase 3 SEACRAFT-2 registrational trial progressing well with Stage 1 randomized data expected in H2 2025 Robust …
Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire
·
March 20, 2025
Enrollment completed in Phase 2a CBeyond™ trial of CB1 inhibitor, nimacimab, in obesity and overweight Faster-than-expected enrollment enables full top-line Phase 2a data in late Q3/early Q4 2025, ahead of schedule; interim analysis removed Phase 2a dosing …
Vaxart Provides Business Update and Reports Full Year 2024 Financial Results
GlobeNewswire
·
March 20, 2025
Initiated Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine constructs with topline data expected as early as mid-2025 Continues per protocol follow-up for the COVID-19 Phase 2b 400-person sentinel cohort Cash, cash equivalents …
Waterstone Financial Declares Regular Quarterly Cash Dividend
GlobeNewswire
·
March 20, 2025
WAUWATOSA, Wis., March 20, 2025 (GLOBE NEWSWIRE) -- On March 20, 2025, the Board of Directors of Waterstone Financial, Inc. (NASDAQ: WSBF) declared a regular quarterly cash dividend of $0.15 per common share. The dividend is payable on May 1, 2025, to …
Tectonic Therapeutic Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
GlobeNewswire
·
March 20, 2025
TX45 Phase 1b trial interim analysis demonstrated meaningful improvements in both left ventricular function and pulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”) Positive …
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Operating and Financial Results
GlobeNewswire
·
March 20, 2025
Tegoprubart used as a key component of immunosuppression regimen in the second transplant of a genetically modified pig kidney into a human conducted at Massachusetts General Hospital Announced positive initial data from first three subjects with type 1 …